Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13).

International journal of biological macromolecules - 15 Nov 2020

Ugurel Osman Mutluhan, Mutlu Ozal, Sariyer Emrah, Kocer Sinem, Ugurel Erennur, Inci Tugba Gul, Ata Oguz, Turgut-Balik Dilek

Abstract excerpt

SARS-CoV-2 has caused COVID-19 outbreak with nearly 2 M infected people and over 100K death worldwide, until middle of April 2020. There is no confirmed drug for the treatment of COVID-19 yet. As the disease spread fast and threaten human life, repositioning of FDA approved drugs may provide fast options for treatment. In this aspect, structure-based drug design could be applied as a powerful approach in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Monophosphate
Share to Betacoronavirus

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to COVID-19 Drug Treatment

Share to Drug Approval

Share to Drug Repositioning

Share to Glucosides

Share to Stilbenes

Share to Vidarabine

Source

Open in PubMed Open full text

Identifiers

PMID: 32980406
DOI: 10.1016/j.ijbiomac.2020.09.138
PMCID: PMC7513821

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13).PMID 32980406Read ↗

Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 HelicaseSemantic proximity Read ↗

Therapeutic potential of compounds targeting SARS-CoV-2 helicaseSemantic proximity Read ↗

Anti-HIV and Anti-HCV drugs are the putative inhibitors of RNA-dependent-RNA polymerase activity of NSP12 of the SARS CoV-2 (COVID-19)Semantic proximity Read ↗

Potential Inhibitors Targeting RNA-Dependent RNA Polymerase Activity (NSP12) of SARS-CoV-2Semantic proximity Read ↗

The SARS-CoV-2 replication-transcription complex is a priority target for broad-spectrum pan-coronavirus drugsSemantic proximity Read ↗

High throughput screening for SARS-CoV-2 helicase inhibitorsSemantic proximity Read ↗

Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp13 HelicaseSemantic proximity Read ↗

Recent advances in small-molecular therapeutics for COVID-19Semantic proximity Read ↗

An Overview of SARS-CoV-2 Potential Targets, Inhibitors, and Computational Insights to Enrich the Promising Treatment StrategiesSemantic proximity Read ↗

An Overview on Drug Evolution and Trials on Pandemic COVID-19 InfectionSemantic proximity Read ↗

In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease InhibitorsSemantic proximity Read ↗

In Silico Drug Discovery: The Next Frontier in the Fight Against SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.